Urine biomarkers may predict aggressive prostate cancer Cadaver lab requiem STDs double in older populations in 10 years Oral anticoagulant options expand Drug News: February/March 2012 Eliquis: third new oral anticoagulant in Canada; Rapaflo for BPH; Gelnique for overactive bladder. Gelnique: new topical gel for overactive bladder First topical gel formulation of oxybutynin to be marketed in Canada. Rapaflo: new alpha antagonist for BPH New drug treats signs, symptoms of benign prostatic hyperplasia. Changes to Canadian guidelines for managing gonorrhea Interim guidelines should be used until the gonorrhea chapter of the Canadian Guidelines on Sexually Transmitted Infections is revised. ‘Movember’ at Memorial Jalyn for moderate-severe BPH New drug for the treatment of moderate to severe symptomatic benign prostatic hyperplasia in men with an enlarged prostate. First Previous 60 61 62 63 64 Next Last
